Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting

October 2, 2023 at 7:35 AM EDT

MADISON, Wis., Oct. 2, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has a 510(k) pending for an online adaptive therapy option*, Cenos™, for its Radixact® System. The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California, October 1-4, 2023. Cenos is designed to enable medical care teams to quickly and efficiently make adjustments, if necessary, to a treatment plan while the patient is still on the treatment table.

Over the course of radiation treatments the size, shape or location of tumors may change and their proximity to organs and other healthy tissue may shift as patients gain or lose weight. Accuray customers are currently able to leverage real-time adaptive therapy through the company's proprietary Synchrony® technology and offline adaptive with PreciseART® radiotherapy to account for some of the anatomical changes that occur during radiation delivery. With the addition of Cenos, Accuray customers will have the ability to perform online adaptation of their treatment plan to account for changes that may occur between treatment sessions. Accuray is committed to offering the most comprehensive adaptive tool set to  provide care teams with choices and the flexibility to optimize and streamline the workflow for each patient, helping to ensure clinical objectives are met.

One of the most important steps in the planning process is contouring – defining the border of the tumor and organs at risk – yet it is extremely labor and time intensive. Automating the contouring portion of the planning process using tools such as the one developed by Limbus AI will make it practical for radiotherapy clinics of all sizes to adopt online adaptive therapy, when needed.

"We're proud of the work we're doing with Limbus and our achievements to date. The goal of Cenos is to provide our customers with a comprehensive and efficient approach to adaptive radiotherapy that includes a solution for making online adaptive therapy feasible for any interested Radixact customer," said Suzanne Winter, President and CEO of Accuray. "We are committed to continuing to evolve our radiation delivery systems to facilitate more personalized care for more cancer patients. Approximately 50% of all cancer patients will need treatment with radiotherapy[1], making it critical that we do everything possible to help ensure that clinicians have the tools to optimize treatments."

"We're very happy to be partnering with Accuray," said Dr Karl Otto, CEO of Limbus AI. "Our AI based technology, Limbus Contour, has seen rapid adoption by over 250 clinics globally. Embedding it into the Cenos online adaptive solution will help provide for accurate and fast contouring essential to real-world clinical implementation of adaptive treatment."

Additional Accuray Highlights at the ASTRO meeting Include:

  • Accuray Financial Services - new: The increasing use of Accuray radiation delivery systems is a reflection of their precision and accuracy, and enhancements introduced in the areas of image quality, speed, versatility, and workflow efficiencies. In the U.S. market Accuray is making it easier for customers to obtain the company's advanced hardware and software or to keep their technology up to date through flexible financing options.

  • Alliance A+ - new: A curated support solutions portfolio covering multiple functions including service, clinical applications and physics, designed to augment medical care team resources and optimize their practice.

  • VitalHold™** Breast Package for the Radixact® System – now 510(k) cleared and obtained CE mark in the EU market: VitalHold enables deep inspiration breath hold (DIBH) treatments on the Radixact System through a fully integrated and automated surface-guided radiotherapy (SGRT) solution. The Radixact System offers compromise-free capabilities to treat the full spectrum of breast cases in as little as two minutes, leveraging both TomoHelical™ (helical delivery) and TomoDirect™ (tangential beams).

  • CyberKnife® System: The CyberKnife S7™ System combines speed, advanced precision, and real-time (AI)-driven motion tracking and synchronization treatment delivery, using Synchrony®, for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments.

*Cenos is 510(k) pending. The solution is not available for sale in the USA. It is not CE marked and availability is subject to regulatory clearance or approval in some markets.
**VitalHold™ availability is subject to regulatory clearance or approval in some markets.

About Limbus AI
Limbus AI's passionate team of healthcare and technology specialists is dedicated to improving cancer care through the development of state-of-the-art software. Our machine learning-based products improve efficiency and clinical workflows in cancer radiation treatment planning. We specialize in the creation of artificial intelligence (AI)-driven automatic contouring algorithms performed on local hardware within the security of the customers' own local network. These unique software solutions enable clinicians to plan accurate treatments quicker, with the same resources - allowing centers to meet the ever-growing demand for radiotherapy. Limbus AI is headquartered in Regina Saskatchewan, Canada. To learn more, visit or follow us on our social media.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit or follow us on Facebook, LinkedIn, Twitter, and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations and goals regarding new products, services and innovations, expectations regarding collaborations and partnerships, expectations regarding continuing to evolve our systems and facilitating more personalized care for cancer patients, patient experiences and patient outcomes. These risks and uncertainties include, but are not limited to, the effect of the current global economic environment, including in connection to the COVID-19 pandemic, on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands; reliance on third party collaborators, partnerships, strategic alliances and joint ventures; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on September 7, 2023, and as updated periodically with the company's other filings with the SEC. 

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact
Beth Kaplan   
Public Relations Director, Accuray                                         
+1 (408) 789-4426                                                                                                                   

1 Atun R. et al. Lancet Oncol 2015; 16: 1153–86


Cision View original content to download multimedia:

SOURCE Accuray Incorporated